Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill

被引:0
作者
Wessel, Rebecca J. [1 ]
Rivera, Christina G. [2 ]
Ausman, Sara E. [3 ]
Martin, Nathaniel [2 ]
Braga, Shienna A. [2 ]
Hagy, Natalie T. [2 ]
Moreland-Head, Lindsay N. [4 ]
Abu Saleh, Omar M. [5 ]
Gajic, Ognjen [6 ]
Jannetto, Paul J. [7 ]
Barreto, Erin F. [2 ]
机构
[1] Mayo Clin, Strategy Dept, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Pharm, 200 1st St SW, Rochester, MN 55905 USA
[3] Mayo Clin Hlth Syst, Dept Pharm, 733 W Clairemont Ave, Eau Claire, WI 54701 USA
[4] Indiana Univ Sch Med, 340 West 10th St,Fairbanks Hall,Suite 6200, Indianapolis, IN 46202 USA
[5] Mayo Clin, Div Publ Hlth Infect Dis & Occupat Med, 200 1st St SW, Rochester, MN 55905 USA
[6] Mayo Clin, Div Pulm & Crit Care Med, 200 1st St SW, Rochester, MN 55905 USA
[7] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
quality improvement; Lean Six Sigma; therapeutic drug monitoring; beta-lactams; medication delivery; INFECTIOUS-DISEASES SOCIETY; IMPLEMENTATION; GUIDELINES; AMERICA;
D O I
10.1093/intqhc/mzae062
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Beta-lactam antibiotics are widely used in the intensive care unit due to their favorable effectiveness and safety profiles. Beta-lactams given to patients with sepsis must be delivered as soon as possible after infection recognition (early), treat the suspected organism (appropriate), and be administered at a dose that eradicates the infection (adequate). Early and appropriate antibiotic delivery occurs in >90% of patients, but less than half of patients with sepsis achieve adequate antibiotic exposure. This project aimed to address this quality gap and improve beta-lactam adequacy using the Define, Measure, Analyze, Improve, and Control Lean Six Sigma quality improvement framework. A multidisciplinary steering committee was formed, which completed a stakeholder analysis to define the gap in practice. An Ishikawa cause and effect (Fishbone) diagram was used to identify the root causes and an impact/effort grid facilitated prioritization of interventions. An intervention that included bundled education with the use of therapeutic drug monitoring (TDM; i.e. drug-level testing) was projected to have the highest impact relative to the amount of effort and selected to address beta-lactam inadequacy in the critically ill. The education and TDM intervention were deployed through a Plan, Do, Study, Act cycle. In the 3 months after "go-live," 54 episodes of beta-lactam TDM occurred in 41 unique intensive care unit patients. The primary quality metric of beta-lactam adequacy was achieved in 94% of individuals after the intervention. Ninety-four percent of clinicians gauged the education provided as sufficient. The primary counterbalance of antimicrobial days of therapy, a core antimicrobial stewardship metric, was unchanged over time (favorable result; P = .73). Application of the Define, Measure, Analyze, Improve, and Control Lean Six Sigma quality improvement framework effectively improved beta-lactam adequacy in critically ill patients. The approach taken in this quality improvement project is widely generalizable to other drugs, drug classes, or settings to increase the adequacy of drug exposure.
引用
收藏
页数:9
相关论文
共 38 条
  • [1] Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
    Abdul-Aziz, Mohd H.
    Alffenaar, Jan-Willem C.
    Bassetti, Matteo
    Bracht, Hendrik
    Dimopoulos, George
    Marriott, Deborah
    Neely, Michael N.
    Paiva, Jose-Artur
    Pea, Federico
    Sjovall, Fredrik
    Timsit, Jean F.
    Udy, Andrew A.
    Wicha, Sebastian G.
    Zeitlinger, Markus
    De Waele, Jan J.
    Roberts, Jason A.
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (06) : 1127 - 1153
  • [2] Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review
    Abdulla, Alan
    van den Broek, Puck
    Ewoldt, Tim M. J.
    Muller, Anouk E.
    Endeman, Henrik
    Koch, Birgit C. P.
    [J]. THERAPEUTIC DRUG MONITORING, 2022, 44 (01) : 112 - 120
  • [3] Al Kuwaiti A, 2017, SAUDI J MED MED SCI, V5, P260, DOI 10.4103/sjmms.sjmms_98_16
  • [4] Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy
    Al-Shaer, Mohammad H.
    Maguigan, Kelly
    Ashton, Jennifer
    Venugopalan, Veena
    Droege, Molly E.
    Philpott, Carolyn D.
    Droege, Christopher A.
    Healy, Daniel P.
    Mueller, Eric W.
    Peloquin, Charles A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [5] "How to" guide for pharmacist-led implementation of beta-lactam therapeutic drug monitoring in the critically ill
    Ausman, Sara N.
    Moreland-Head, Lindsay M.
    Abu Saleh, Omar J.
    Jannetto, Paul G.
    Rivera, Christina W.
    Stevens, Ryan J.
    Wessel, Rebecca M.
    Wieruszewski, Patrick F.
    Barreto, Erin
    BLOOM Study Grp
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (08): : 964 - 975
  • [6] Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118
  • [7] Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study
    Barreto, Erin F.
    Chitre, Pooja N.
    Pine, Kathleen H.
    Shepel, Kathryn K.
    Rule, Andrew D.
    Alshaer, Mohammad H.
    Abdul Aziz, Mohd Hafiz
    Roberts, Jason A.
    Scheetz, Marc H.
    Ausman, Sara E.
    Moreland-Head, Lindsay N.
    Rivera, Christina G.
    Jannetto, Paul J.
    Mara, Kristin C.
    Boehmer, Kasey R.
    [J]. THERAPEUTIC DRUG MONITORING, 2023, 45 (04) : 508 - 518
  • [8] Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy
    Barreto, Erin F.
    Chang, Jack
    Bjergum, Matthew W.
    Gajic, Ognjen
    Jannetto, Paul J.
    Mara, Kristin C.
    Meade, Laurie A.
    Rule, Andrew D.
    Vollmer, Kathryn J.
    Scheetz, Marc H.
    [J]. PHARMACOTHERAPY, 2023, 43 (11): : 1112 - 1120
  • [9] Barreto Erin F, 2021, Crit Care Explor, V3, pe0446, DOI 10.1097/CCE.0000000000000446
  • [10] Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum
    Bjergum, Matthew W.
    Barreto, Erin F.
    Scheetz, Marc H.
    Rule, Andrew D.
    Jannetto, Paul J.
    [J]. JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (05) : 1202 - 1212